Analyzing OptiNose (OPTN) & Editas Medicine (NASDAQ:EDIT) – TrueBlueTribune
|
Analyzing OptiNose (OPTN) & Editas Medicine (NASDAQ:EDIT)
TrueBlueTribune It is developing a genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR) technology. CRISPR uses a protein-ribonucleic acid (RNA) complex composed of an enzyme, including either CRISPR associated protein 9 … |
